ImmunityBio Faces Legal and Regulatory Challenges After FDA Rebuke

ImmunityBio's stock plunged 21% after an FDA warning letter over misleading ANKTIVA claims, sparking investor lawsuits. The firm is implementing new compliance measures while its core clinical trials advance.

The biotechnology firm ImmunityBio is confronting a significant crisis of confidence following regulatory action by the U.S. Food and Drug Administration (FDA). This comes despite the company reporting explosive revenue growth last year. A formal FDA warning has triggered a steep decline in market value and prompted a wave of investor lawsuits, leading management to initiate a series of corrective measures.

Legal Repercussions Follow FDA Warning

At the core of the turmoil is a warning letter issued by the FDA in late March. The agency accused ImmunityBio of overstating the efficacy of its flagship therapy, ANKTIVA, in promotional materials. According to the FDA, a company podcast and a television advertisement presented misleading claims about the drug's effectiveness and suggested it could treat a wider range of cancers than its current approval for non-muscle invasive bladder cancer (NMIBC) allows.

The market reaction was severe. The company's stock plummeted approximately 21%, erasing nearly $2 billion in market capitalization. In a direct legal consequence, several law firms filed class-action lawsuits against ImmunityBio yesterday. These suits allege that company leadership misled investors with false statements about ANKTIVA's commercial potential between mid-January and the end of March.

Company Implements New Safeguards

In a comprehensive response to the FDA, ImmunityBio has begun a damage-control campaign. The company confirmed it has removed the cited podcast from its official website and is requesting its removal from third-party platforms. Management also stated that the television commercial in question never actually aired publicly.

To prevent future violations, CEO Richard Adcock announced stricter internal review protocols. Executive teams will now be required to undergo mandatory compliance training. Furthermore, the company plans to engage external consultants to provide additional oversight for high-visibility promotional campaigns.

Underlying Business Maintains Momentum

Separate from its regulatory and legal troubles, ImmunityBio's core clinical operations continue to advance. A key trial, known as QUILT-2.005, which is testing ANKTIVA in combination with standard therapy for specific bladder cancer patients, completed patient recruitment in February. The company's financial position appears robust following a strong 2025, during which it generated $113 million in product revenue—a staggering 700% increase—and holds cash reserves of approximately $243 million.

The next major operational milestone is slated for the fourth quarter of 2026. ImmunityBio intends to submit an application for expanded regulatory approval of ANKTIVA based on final study data expected by that time. The critical task for management in the interim will be to demonstrate the effectiveness of its new compliance framework and ensure the mounting legal challenges do not derail its commercial trajectory.